Background: Ginkgo biloba is a common symptomatic treatment for cognitive impairment, although data on its efficacy are controversial.
Objective: The aim of the current study was to evaluate the effectiveness of standardized Ginkgo
biloba extract EGb761®
) for the improvements of cognitive functions over 24 months in
a local cohort of patients diagnosed with amnestic mild cognitive impairment (aMCI).
Methods: This multicentre non-interventional study included 500 eligible patients with a MCI treated with 120 mg/day standardized Ginkgo biloba extract EGb761®
). Patients were evaluated using several scales for assessment of cognition, memory, activities of daily living, and depression (MMSE, FAQ, CGI, HAM-D) at baseline and every 6 months after that for a 24-month period. The median change in MMSE at the 24-month follow-up was the primary outcome of the
Results: A statistically significant increase of 2 points in the median MMSE score was obtained. In
patients with other concomitant cognitive disorders, the improvement in MMSE was less significant. Tanakan®
improved memory impairment (using the delayed recall test) and the ability to accomplish activities of daily living (mean FAQ score, 1.7); it also decreased the severity of depression (mean HAM-D score, 2.4) at the end of the study. More than 80% of the patients showed minimal improvement of their condition as assessed by the CGI-Improvement Scale.
Conclusions: The administration of EGb761®
) led to a significant improvement of cognitive dec